Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Dose Escalation and Expansion Study of HPB-092 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (RR-AML)

NCT07137637 is registered in ClinicalTrials.gov with Hangzhou Polymed Biopharmaceuticals, Inc. as lead sponsor.

NCT NCT07137637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07137637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Dose Escalation and Expansion Study of HPB-092 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (RR-AML)
Lead sponsor
Hangzhou Polymed Biopharmaceuticals, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 10, 2026
Completion date
December 31, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and refractory acute myeloid leukemia (rr-aml)